Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

March 15, 2011 (Vol. 31, No. 6)

Status of Cell and Gene Therapy Keeps Vacillating

Recent High-Profile Success of Dendreon's Provenge Has Not Quelled Widespread Skepticism and Skittishness

  • At Phacilitate’s recent “Cell & Gene Therapy Forum”, enthusiasm greeted reported advances in the research laboratory and successes in the commercial arena for technologies that represent high-risk ventures for the companies developing them. Excitement also accompanied the introduction of pioneering therapeutic strategies that epitomize the promise of personalized medicine. ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.